Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2009 by Harbin Medical University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Harbin Medical University
ClinicalTrials.gov Identifier:
NCT01024179
First received: December 1, 2009
Last updated: December 4, 2009
Last verified: December 2009

December 1, 2009
December 4, 2009
December 2009
December 2010   (final data collection date for primary outcome measure)
To investigate the relationship between initial plaque characteristics and stent surface coverage after sirolimus-eluting stent implantation. [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01024179 on ClinicalTrials.gov Archive Site
  • Relationship between tissue prolapse and initial plaque characteristics [ Time Frame: Post-intervention ] [ Designated as safety issue: Yes ]
  • Comparison of the differences in vascular response (surface coverage and malapposition) between CTO and non- CTO lesions. [ Time Frame: 6-month ] [ Designated as safety issue: Yes ]
  • Late stent malapposition( by OCT and IVUS ). [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Relationship between initial lesion characteristics and stent surface coverage pattern after SES implantation. [ Time Frame: 12 -month ] [ Designated as safety issue: Yes ]
  • Comparison of the differences in stent surface coverage between CTO and non- CTO lesions. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns
Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns After Sirolimus-eluting Stent Implantation Assessment by Optical Coherence Tomography

Vulnerable plaque characterized by thin fibrous cap and large lipid core is an independent risk factor for most of acute cardiac event. Current clinical data showed that thin-cap fibroatheroma was more frequently observed in patients with ACS than SAP. Further OCT study indicated that patients with ACS had significantly higher incidence of incomplete neointimal coverage and malapposition after DES implantation than those with SAP. These findings imply that initial native lesion characteristics may be related to different vessel response (neointimal coverage and malapposition) after stenting. However, there is little data on the relationship between plaque characteristics and vascular response to DES after stent implantation evaluated by OCT.

Therefore, this study was designed to investigate the relationship between initial plaque characteristics and stent surface coverage or late malapposition after SES implantation. The investigators will use high resolution OCT to assess the initial culprit plaque morphology and subsequent vascular response after SES stenting at the time points of post-stenting, 6 months and 12 months. IVUS will also be performed to evaluate the tissue protrusion, malapposition, vessel remodeling at the same time points.

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Coronary Artery Disease
Device: Polymer-based sirolimus-eluting stent (Partner stent )
Partner stent (polymer-based sirolimus-eluting stent) implanted in culprit coronary artery
  • Active Comparator: Group B: CTO
    Chronic total occlusion
    Intervention: Device: Polymer-based sirolimus-eluting stent (Partner stent )
  • Active Comparator: Group A : Non-CTO

    Non-chronic total occlusion :

    1. Fibrous plaque+fibro-calcific plaque + Lipid plaque(<2 quadrants )
    2. Lipid-rich plaque ( ≥2 quadrants )
    Intervention: Device: Polymer-based sirolimus-eluting stent (Partner stent )
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
90
June 2011
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria

General Inclusion Criteria:

  1. Age:18-75Y
  2. Patients with stable angina or acute coronary syndrome considered suitable for coronary revascularization.
  3. Patient or legal guardian understands and agrees to comply with all specified study requirements and provides written informed consent.

Angiographic Inclusion Criteria:

  1. Significant coronary de novo lesion (> 70% by visual estimation).
  2. Target lesion is de novo native coronary artery lesion that can be treated with 1-2 stents.
  3. Reference vessel diameter of 2.5 to 4.0 mm.

Exclusion Criteria:

General Exclusion Criteria:

  1. ST-segment elevation myocardial infarction within 7 days prior to the index procedure.
  2. Previous CABG.
  3. Life expectancy <12 months due to another medical condition.
  4. Contraindication to antiplatelet therapy
  5. Creatinine level more than 2.0mg/dL or ESRD.
  6. Severe hepatic dysfunction (more than 3 times normal reference values).
  7. Planned surgery procedure ≤ 6 months post-index procedure.
  8. Known allergy to stainless steel or a history of hypersensitivity to sirolimus or structurally related compounds.
  9. Female of childbearing potential with a positive pregnancy test within 7 days before the index procedure, or lactating, or intends to become pregnant during the 12 months post index procedure.
  10. Patient is not clinically appropriate for OCT evaluation in the opinion of the investigator.

Angiographic Exclusion Criteria:

  1. Study lesion is ostial in location (within 3.0 mm of vessel origin).
  2. Study lesion involving arterial segments with highly tortuous anatomy.
  3. Complex lesion morphologies (aorto-ostial, bifurcation needs two stents technique, left main, severe thrombi, heavy calcification).
Both
18 Years to 75 Years
No
Contact: Bo Yu, MD,PhD 86-0451-86605180 yubodr@163.com
China
 
NCT01024179
HMUOCT-PLAQUE
No
Bo Yu, Department of Cardiology of The Second Affiliated Hospital of Harbin Medical University
Harbin Medical University
Not Provided
Principal Investigator: Bo Yu, MD.PhD The Second Affiliated Hospital of Harbin Medical University
Harbin Medical University
December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP